GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction: Design and Rationale for the Functional Impact of GLP-1 for Heart Failure Treatment Study
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
H eart failure (HF) is a leading cause of mortality and mor- bidity in the industrialized world and imposes a substantial burden on public health.In the United States, HF is the primary cause of death for more than 60 000 people annually and a contributing factor in over 282 000 cases. 1 Despite guidelinerecommended therapy for patients with HF and reduced ejection fraction, 1 the 1-year mortality in patients with New York Heart Association (NYHA) functional class III to IV HF on maximal medical therapy is 35% to 40%. 2 Based on recent estimates, approximately 5.1 million adult Americans have HF, and projections show that by the year 2030 the prevalence of HF in the United States will increase by 25%. 2 By any metric, HF imposes a major public health and financial burden on society.The lack of new disease-modifying pharmacological therapy for HF over the past 2 decades further amplifies these concerns.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191261 · Cited by 3,140
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e318282ab8f · Cited by 1,294
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“02).(40) In a randomized, double-blinded, crossover clinical trial in 20 patients with a low LVEF (<35%) and NYHA III-IV HF symptoms,(40) Nathanson et al(41) reported that the GLP-1 agonist exenatide significantly increased cardiac index and decreased pulmonary wedge pressure at 3 and 6 hours after the infusion had be…”
BackgroundSokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Is the Failing Heart Energy Starved?: On Using Chemical Energy to Support Cardiac Function
Ingwall, J. S., & Weiss, R. G. (2004) · Circulation Research · doi:10.1161/01.res.0000137170.41939.d9 · Cited by 604 · cited 1×
“Why Cardiac Metabolism as a Therapeutic Target for HF Even in the absence of acute coronary insufficiency, an increasing body of literature supports the concept of the failing heart as an energy-starved organ.(18,19) The heart consumes more energy per gram than any other organ, and myocardial metabolic demands are fur…”
BackgroundNoyan-Ashraf, M. H., Shikatani, E. A., Schuiki, I., Mukovozov, I., Wu, J., Li, R.-K., Volchuk, A., Robinson, L. A., Billia, F., Drucker, D. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.091215 · Cited by 259 · cited 1×
“As illustrated in the Figure, recent studies indicate that GLP-1 receptor binding activates adenylate cyclase and phosphorylates (activates) the cAMP-dependent protein kinase (AMPK).(33) In turn, activated AMPK enhances insulin-dependent signaling, increases glucose uptake and provides other cardioprotective actions.”
Background
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
Self-citationThe Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166
Metadata
- Authors
- Margulies, K. B., Anstrom, K. J., Hernandez, A. F., Redfield, M. M., Shah, M. R., Braunwald, E., & Cappola, T. P.
- Venue
- Circulation: Heart Failure
- Published
- 2014-07
- Volume
- 7
- Issue
- 4
- Pages
- 673-679
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W2129126699
- Cited by
- 46
- References
- 7
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction: Design and Rationale for the Functional Impact of GLP-1 for Heart Failure Treatment Study. https://app.cochat.ai/papers/10.1161/circheartfailure.114.000346
- The paper
- Margulies, K. B., Anstrom, K. J., Hernandez, A. F., Redfield, M. M., Shah, M. R., Braunwald, E., & Cappola, T. P. (2014). GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction: Design and Rationale for the Functional Impact of GLP-1 for Heart Failure Treatment Study. Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.114.000346
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.